Skip to main content
Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
4.840
+0.010 (0.21%)
At close: Apr 28, 2026, 4:00 PM EDT
4.840
0.00 (0.00%)
Pre-market: Apr 29, 2026, 6:19 AM EDT

Myriad Genetics Revenue

In the year 2025, Myriad Genetics had annual revenue of $824.50M, down -1.56%. Myriad Genetics had revenue of $209.80M in the quarter ending December 31, 2025, a decrease of -0.38%.

Revenue (ttm)
$824.50M
Revenue Growth
-1.56%
P/S Ratio
0.55
Revenue / Employee
$305,370
Employees
2,700
Market Cap
457.10M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025824.50M-13.10M-1.56%
Dec 31, 2024837.60M84.40M11.21%
Dec 31, 2023753.20M74.80M11.03%
Dec 31, 2022678.40M-12.20M-1.77%
Dec 31, 2021690.60M133.60M23.99%
Dec 31, 2020 Pro Pro Pro
Jun 30, 2020 Pro Pro Pro
Jun 30, 2019 Pro Pro Pro
Jun 30, 2018 Pro Pro Pro
Jun 30, 2017 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
NeoGenomics 727.33M
OPKO Health 606.88M
GeneDx Holdings 427.54M
CareDx 379.81M
Castle Biosciences 344.23M
Fulgent Genetics 322.67M
FONAR 106.03M
Prenetics Global 92.39M
Revenue Rankings

MYGN News

More News